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Background: We recently synthesized a hydrophilic polymer, poly(N-(2-hydroxypropyl)methacrylamide-co-N-(3-
azidopropyl)methacrylamide), p(HPMA-co-AzMA), by RAFT polymerization using a novel azide-containing methacrylamide
monomer that through a post modification strategy using click chemistry enabled facile preparation of a panel of versatile
and well-defined bioconjugates. In this work we screen a panel of different molecular weight (Mw) fluorescently tagged
p(HPMA-co-AzMA) in healthy mice, by live bioimaging, to select an extended circulatory half-life material for investigating
joint accumulation in a murine collagen antibody-induced arthritis model.
Findings: Fluorescence image analysis revealed half-lifes of <20 min, 2.8 h and 6.4 h for p(HPMA-co-AzMA) of 15, 36 and
54 kDa, respectively, with ~10% polymer retained in the blood after 24 h for the highest Mw. p(HPMA-co-AzMA)
of 54 kDa showed enhanced accumulation in the joints of the arthritic mouse model with a bioavailability
(AUC = 1783% · h) ~12 times higher (P = 0.01) than healthy control (AUC = 148% · h).
Conclusions: p(HPMA-co-AzMA) of 54 kDa exhibited extended circulatory half-life and preferential accumulation
in inflamed joints of a murine model of rheumatoid arthritis (RA). This combined with well-defined polymer size
and versatility for conjugation of a range of biomolecules promotes p(HPMA-co-AzMA) for potential applications
in the delivery of drugs for treatment of RA.
Keywords: Arthritis, Collagen Antibody-Induced Arthritis, Extended circulation, HPMA, in vivo, Image analysis, Joint
accumulation, N-(3-azidopropyl)methacrylamide), Poly(N-(2-hydroxypropyl)methacrylamide)Findings
Introduction
Rheumatoid arthritis (RA) is a chronic progressive auto-
immune disease affecting ~ 1% of the population causing
cartilage and bone destruction in synovial joints [1]. The
pathogenesis involves synovial infiltration by circulatory
immune cells that induce inflammation, modulated pre-
dominantly by proinflammatory cytokines such as tumor
necrosis factor alfa (TNFα) [2,3]. Common clinical
treatments include nonsteroidal anti-inflammatory drugs
(NSAIDs), glucocorticoids, and disease-modifying anti-
rheumatic drugs (DMARDs) such as anti-TNFα antibodies.* Correspondence: kenh@inano.au.dk
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unless otherwise stated.Although effective in many patients, these therapeutics
have associated side-effects such as myelosuppression
and increased infection risk, primarily due to a general
systemic immune suppression that necessitates alternative
approaches [1,4]. RA associated angiogenesis, necessary
for formation of pannus and invasion of inflammatory
cells into the synovial tissue, has been identified to estab-
lish a macromolecular retention effect [5-7], conceptually
similar to the EPR effect for tumors [8]. Hydrophilic
polymers synthesized with high molecular weights (Mw)
enable the construction of polymer macromolecular drugs
[9] with extended blood circulation and specific targeting
to arthritic joints. This has been used for local suppression
of proinflammatory cytokines such as TNFα [10] that
may increase the clinical efficacy and reduce generalized
side effects.
The field of polymer therapeutics requires increased
attention to defining and minimizing macromoleculel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Synthesis and functionalization of the p(HPMA-co-AzMA) copolymer as a versatile method for production of polymer bioconjugates
(Reproduced from ref. 13 with permission from John Wiley and Sons).
Figure 2 Blood circulation profiles. Blood circulation profiles of
dye-labeled p(HPMA-co-AzMA) of 15, 36 and 54 kDa (PBS as
control) in BALB/c mice. Polymer levels were normalized to the value
measured at 5 min. 10% of the 54 kDa polymer was retained in the
blood at 24 h Polymer bioavailability (AUC) are 698, 313 and 45% · h for
polymers of 54, 36 and 15 kDa, respectively. Polymer circulation half-life
was calculated to 6.4, 2.8 and < 0.33 h for polymers of 54, 36 and
15 kDa, respectively. Averages of n = 3 mice are shown with SEM.
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on pharmacokinetics, safety and efficacy of polymer
therapeutics and to identify precise polymer characteris-
tics required for delivery e.g. to RA affected tissue [11,12].
We have recently synthesized a novel azide containing
copolymer, poly(N-(2-hydroxypropyl)methacrylamide-co-
N-(3-azidopropyl)methacrylamide), (p(HPMA-co-AzMA)),
through a versatile post-modification procedure to produce
a panel of well-defined polymer bioconjugates of narrow
PdI (Figure 1) [13]. Compared to existing bioconjugation
strategies for RA [14,15], this may provide superior polymer
characteristics in terms of flexibility for modification and
low polydispersity.
Research hypothesis
We hypothesize that the p(HPMA-co-AzMA) constructs
will exhibit prolonged blood circulation and specific
accumulation in inflamed joints in a murine model of
rheumatoid arthritis supporting its potential therapeutic
application for RA.
Methods
For blood circulation studies, a PBS solution (100 μL) of
p(HPMA-co-AzMA) polymers (4 mg/kg) of different
Mw (15, 36 and 54 kDa) labeled with an Atto680 dye
(ATTO-TEC GmbH, Siegen, Germany), or PBS only
control was administered intravenously (i.v.) in healthy
BALB/c male mice (8 week-old, Taconic Europe, Ry,
Denmark). Blood volumes (~80 μL, max 2 pr. animal) were
sampled from 5 min up to 24 h post-injection and the blood
plasma was subsequently transferred to narrow 20 uL glass
capillary tubes (minicaps, Hirschmann) and imaged with the
IVIS® Spectrum using a 675/720 nm filterset and analyzed
using the Living Image software version 4.3 (PerkinElmer).
Nine week-old, male, DBA/1 (Taconic Europe, Ry,
Denmark) were used for the collagen antibody-induced
arthritis (CAIA) model [16] with intraperitoneal (i.p.)
injection of the monoclonal antibody mix (Arthrogen-CIA®arthritogenic monoclonal antibody 5 clones cocktail kit,
Chondrex, Inc. Redmond, USA) and a subsequent LPS injec-
tion 3 days later. The severity of the arthritic condition was
monitored by daily clinical scoring of joints (1–4) [16] with
symptoms developing ~ day 3 and peaking around day 8.
Healthy control mice (DBA/1) were injected i.p. with PBS.
For the joint accumulation studies, a PBS solution of the
54 kDa Atto680-labeled (0.57 w/w%) p(HPMA-co-AzMA),
or the free dye, was administered by intravenous (i.v.)
injection to arthritic and control animals at a polymer dose
of 4 mg/kg or the dye-equivalent amount (22.6 ug/kg) of
free dye. This dose was comparable to existing studies
[17,18] and at a concentration by which the polymer
conjugated dye could be easily visualized using in vivo
fluorescence imaging. Joint fluorescence was monitored
before, and up to, 24 h post-injection by IVIS Spectrum
Figure 3 Dye-labeled p(HPMA-co-AzMA) joint accumulation
profiles. 62% of the 54 kDa dye-labeled copolymer (Pol-dye) was
retained in arthritic joints of DBA/1 mice at 24 h. Polymer bioavailability
(AUC) was 1783 and 148% · h in arthritic (n = 16 joints, 4 mice) and
healthy (n = 16 joints, 4 mice) joints. Dye alone was included as control
with AUC of 4.48 and 8.96% · h in arthritic (n = 4 joints, 1 mouse) and
healthy (n = 8 joints, 2 mice). Joint polymer levels are normalized to
the highest mean value and averages shown with SEM.
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Multispectral fluorescence images covering the absorption-
emission profile of the Atto680 dye were acquired using
the Living Image software (PerkinElmer). Images were
spectrally unmixed to subtract background fluorescence,
which enabled the total fluorescence emission from
joint areas from each mouse to be quantified. Measured
intensities of the fluorescence emission are generally
linear dependent on fluorophore concentration, extinction
coefficient and quantum yield, which enables a direct
correlation to polymer levels in the blood or tissue [19].Figure 4 Paw fluorescence from arthritic and non-arthritic mice 24 h
non-arthritic mice 24 h post-injection of a 54 kDa dye-labeled copolymer (P
unmixed to subtract background fluorescence enabling visualization of the
examples of polymer accumulation in arthritic joints, minute amounts of p
control that correspond to Figure 3.All image data was analyzed using Prism (GraphPad
Software Inc.). Blood polymer levels were normalized
to the value measured at 5 min and joint polymer levels
to the highest mean value and presented as % with
SEM. Students t-test was performed to determine data
significance.
All procedures of animal work were performed according
to international recognized guidelines and the animal
experimental protocols approved by ‘The Experimental
Animal Inspectorate in Denmark’ under The Danish
Veterinary and Food Administration, Ministry of Food,
Agriculture and Fisheries (Registration number: 2013 −
15 − 2934 − 00789-C2, issue date: March 5, 2013).
Results and discussion
Blood circulation profiles (Figure 2) constructed from
blood plasma fluorescent polymer levels showed a Mw-
dependent prolonged blood retention of the copolymers.
At 24 h, the 54 kDa copolymer was still retained in the
blood at ~10% and accordingly displayed a significant
(P < 0.03) higher bioavailability (area under the curve,
AUC = 698% · h) compared to 36 kDa (AUC = 313% · h)
and 15 kDa (AUC = 45% · h) polymers [see Additional
file 1: Figure S1]. First order clearance kinetics were
modeled from 1 h post i.v. injection of dye-labeled
copolymers of different Mw and exhibited a half-life
of < 20 min for polymers of 15 kDa that increased up
to 2.8 h for 36 kDa and 6.4 h for 54 kDa polymers, in
general accordance with previous studies on HPMA
copolymers [18]. Renal filtration commonly occurs for
polymers with a hydrodynamic radius below 5 nm that
corresponds to ~30 to 50 kDa Mw, however, with renal
clearance of linear polymers, such as in this work, being
up to 10 times higher than those of more globular-shape
[20]. In this work, the highest Mw p(HPMA-co-AzMA)post-injection. IVIS Spectrum in vivo imaging of arthritic and
ol-dye) and dye alone. Multispectral fluorescence images were
dye and dye-labeled polymers. The images show representative
olymer in joints of healthy mice, and no presence of dye alone as
Figure 5 Correlation plot of arthritic score against polymer
accumulation in DBA/1 mice joints at 24 h. Spearman correlation
coefficient, r = 0.89 with P < 0.0001 supports a direct correlation.
Ebbesen et al. Molecular and Cellular Therapies 2014, 2:29 Page 4 of 5
http://www.molcelltherapies.com/content/2/1/29did not seem to be excessively larger than the renal
clearance limit, but still exhibiting prolonged circulation,
and was, thus, selected for evaluation in arthritic mice.
Enhanced passive accumulation of the 54 kDa dye-
grafted p(HPMA-co-AzMA) in the joints of arthritic mice
compared to healthy was demonstrated (Figure 3 and
Figure 4) with the bioavailability in arthritic tissue
(AUC = 1783% · h) being ~12 times higher (P = 0.01)
compared to healthy tissue (AUC = 148% · h) (see
Additional file 2: Figure S2). Additionally, at 24 h,
polymer levels in the blood of arthritic animals were lower
than that of healthy (see Additional file 3: Figure S3), but
showed a higher level in arthritic paws compared to
healthy (Figure 3 and Figure 4). This suggests the polymer
to be escaping blood circulation faster in the arthritic
mice, probably due to accumulation in the arthritic
joints. The polymer levels in healthy mice joints initially
increased by 63% within 10 minutes but subsequently
quickly declined, probably as a result of blood clearance of
the polymer in general and a healthy microvasculature not
exhibiting permeability and polymer extravasation effects.
Free dye in arthritic or non-arthritic tissue was rapidly
excreted and almost cleared before the first time point
at 10 min (Figure 3, 10 min).
The arthritic scores, as an indicator of inflamed severity,
were not entirely uniform with individual mice exhibiting
combinations of joint scores (1–4). A Spearman test of
polymer accumulation (at 24 h) and arthritic score correl-
ation was, therefore, performed (Figure 5), supporting
strong correlation between polymer accumulation and the
arthritic condition (r = 0.89, P < 0.0001).
In summary, this work demonstrates the in vivo charac-
teristics of a new azide containing copolymer, (p(HPMA-
co-AzMA)), which offers a more versatile and well-defined
alternative to existing bioconjugate systems. Attractivein vivo properties such as prolonged blood retention and
specific accumulation in inflamed joints of RA illustrate
the potential of the material for systemic delivery of anti-
inflammatory drugs for local effects in the treatment of RA.
Additional files
Additional file 1: Figure S1. Blood plasma bioavailability (AUC), in
healthy BALB/c mice, of p(HPMA-co-AzMA) of 15, 36 and 54 kDa
calculated from blood plasma polymer profiles in Figure 2.
Additional file 2: Figure S2. Bioavailability (AUC) of dye-labeled
p(HPMA-co-AzMA) of 54 kDa and free dye in arthritic and healthy joints.
AUC’s are calculated from p(HPMA-co-AzMA) joint accumulation profiles
in Figure 3.
Additional file 3: Figure S3. Blood plasma levels of dye-labeled p
(HPMA-co-AzMA) and free dye at 24 h. Polymer levels in the blood indicate
that the polymer escapes blood circulation faster in the arthritic mice possible
due to accumulation in the arthritic mice joints. Levels are normalized to the
highest mean value and averages shown with SEM.
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